JP2002512029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512029A5 JP2002512029A5 JP2000544795A JP2000544795A JP2002512029A5 JP 2002512029 A5 JP2002512029 A5 JP 2002512029A5 JP 2000544795 A JP2000544795 A JP 2000544795A JP 2000544795 A JP2000544795 A JP 2000544795A JP 2002512029 A5 JP2002512029 A5 JP 2002512029A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- peptide
- poly
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108020004707 nucleic acids Proteins 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 33
- 150000007523 nucleic acids Chemical class 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 238000000034 method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98107268.9 | 1998-04-21 | ||
| EP98107268 | 1998-04-21 | ||
| PCT/EP1999/002695 WO1999054463A2 (en) | 1998-04-21 | 1999-04-21 | Human k+ ion channel and therapeutic applications thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009160236A Division JP2009235091A (ja) | 1998-04-21 | 2009-07-06 | ヒトｋ＋イオンチャンネルおよびその治療的適用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002512029A JP2002512029A (ja) | 2002-04-23 |
| JP2002512029A5 true JP2002512029A5 (enExample) | 2006-06-15 |
Family
ID=8231794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000544795A Withdrawn JP2002512029A (ja) | 1998-04-21 | 1999-04-21 | ヒトｋ＋イオンチャンネルおよびその治療的適用 |
| JP2009160236A Pending JP2009235091A (ja) | 1998-04-21 | 2009-07-06 | ヒトｋ＋イオンチャンネルおよびその治療的適用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009160236A Pending JP2009235091A (ja) | 1998-04-21 | 2009-07-06 | ヒトｋ＋イオンチャンネルおよびその治療的適用 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US6638736B1 (enExample) |
| EP (1) | EP1073738B1 (enExample) |
| JP (2) | JP2002512029A (enExample) |
| AT (1) | ATE278017T1 (enExample) |
| CA (1) | CA2323571A1 (enExample) |
| DE (1) | DE69920681T2 (enExample) |
| DK (1) | DK1073738T3 (enExample) |
| ES (1) | ES2230852T3 (enExample) |
| PT (1) | PT1073738E (enExample) |
| WO (1) | WO1999054463A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69920681T2 (de) * | 1998-04-21 | 2005-09-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Humaner k+ ionenkanal und therapeutische verwendungen davon |
| DE10025620A1 (de) * | 2000-05-24 | 2001-12-06 | Forschungsgesellschaft Genion | Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten |
| DE10224534A1 (de) | 2002-05-31 | 2003-12-11 | Juergen Dolderer | Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung |
| EP1805222B1 (en) | 2004-10-01 | 2011-02-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Antibodies directed to the mammalian eag1 ion channel protein |
| MX2007003865A (es) * | 2004-10-01 | 2009-06-17 | Ct Investig Y Estudios Del Ipn | Métodos para el diagnóstico temprano de infecciones virales y enfermedades inflamatorias o de la predisposición de un individuo a desórdenes proliferativos o hiperplasia. |
| AU2013201604B2 (en) * | 2007-04-13 | 2014-08-14 | Southern Research Institute | Anti-angiogenic agents and methods of use |
| ES2334084B1 (es) * | 2007-12-21 | 2011-01-24 | Inst Cientifico Tecnol Navarra | Marcadores geneticos para el pronostico de la esclerosis multiple. |
| US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
| TWI570415B (zh) * | 2015-10-02 | 2017-02-11 | A spring probe having an outer sleeve and a probe device having the spring probe | |
| EP3195727A1 (en) | 2016-01-22 | 2017-07-26 | Forschungsinstitut Fur Biologischen Landbau (FiBL) | Duddingtonia flagrans strain and feed additive formulation for biological pest control |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB9303210D0 (en) | 1993-02-17 | 1993-03-31 | Univ Manitoba | Cancer treatment |
| AU665341B2 (en) | 1990-12-18 | 1996-01-04 | Wellcome Foundation Limited, The | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| JP2000515498A (ja) * | 1996-07-02 | 2000-11-21 | ノバルテイス・コンシユーマー・ヘルス・エス・アー | 抗ヒスタミン化合物とテルペノイド化合物の組み合わせからなる局所組成物 |
| US6610827B1 (en) * | 1997-10-29 | 2003-08-26 | Elan Pharmaceuticals, Inc. | Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor |
| DE69920681T2 (de) * | 1998-04-21 | 2005-09-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Humaner k+ ionenkanal und therapeutische verwendungen davon |
-
1999
- 1999-04-21 DE DE69920681T patent/DE69920681T2/de not_active Expired - Lifetime
- 1999-04-21 DK DK99920731T patent/DK1073738T3/da active
- 1999-04-21 AT AT99920731T patent/ATE278017T1/de not_active IP Right Cessation
- 1999-04-21 PT PT99920731T patent/PT1073738E/pt unknown
- 1999-04-21 ES ES99920731T patent/ES2230852T3/es not_active Expired - Lifetime
- 1999-04-21 JP JP2000544795A patent/JP2002512029A/ja not_active Withdrawn
- 1999-04-21 WO PCT/EP1999/002695 patent/WO1999054463A2/en not_active Ceased
- 1999-04-21 EP EP99920731A patent/EP1073738B1/en not_active Expired - Lifetime
- 1999-04-21 CA CA002323571A patent/CA2323571A1/en not_active Abandoned
-
2000
- 2000-10-23 US US09/694,777 patent/US6638736B1/en not_active Expired - Fee Related
-
2002
- 2002-07-01 US US10/188,308 patent/US7364730B2/en not_active Expired - Fee Related
- 2002-07-01 US US10/188,296 patent/US7364845B2/en not_active Expired - Fee Related
- 2002-07-01 US US10/188,297 patent/US7314914B2/en not_active Expired - Fee Related
- 2002-07-01 US US10/188,341 patent/US7129207B2/en not_active Expired - Fee Related
-
2006
- 2006-11-30 US US11/633,085 patent/US20080020406A1/en not_active Abandoned
-
2009
- 2009-06-09 US US12/480,913 patent/US20100021467A1/en not_active Abandoned
- 2009-07-06 JP JP2009160236A patent/JP2009235091A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6150092A (en) | Antisense nucleic acid compound targeted to VEGF | |
| ES2661310T3 (es) | Proteínas mirac | |
| EP1623997B1 (en) | Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours | |
| JP2007537197A5 (enExample) | ||
| WO2002008261A2 (en) | Bstp-trans protein and related reagents and methods of use thereof | |
| JP2007506417A5 (enExample) | ||
| CA2486252A1 (en) | Methods for screening for agents that modulate hepatocellular carcinoma development | |
| JP2025020207A (ja) | 血液脳関門の標的化に有用な組成物および方法 | |
| US6417338B1 (en) | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy | |
| JP2002512029A5 (enExample) | ||
| TW416960B (en) | Reshaped human antibody to human interleukin-8 | |
| CN112870362B (zh) | Circ-MET-1214和/或Circ-M50作为靶点在制备抗肿瘤药物中的用途 | |
| WO2012015836A1 (en) | Highly potent peptides to control cancer and neurodegenerative diseases | |
| KR960015442B1 (ko) | 맥관인자 | |
| WO2023179789A1 (zh) | 干扰趋化素样因子超家族成员6(cmtm6)表达的基因治疗载体的制备和抗肿瘤应用 | |
| JP2003534786A (ja) | 化学療法および放射線感作物質を用いた腫瘍性疾患を処置するための組成物および方法 | |
| DE69925271T2 (de) | Angiostatin-bindendes protein | |
| CN106701902B (zh) | Foxr2基因和表达产物在肝癌诊断与治疗中的应用 | |
| US10314889B2 (en) | Suppression of allergic lung inflammation and hyperreactivity | |
| JP2001516568A (ja) | 医薬および診断剤の調製のためのプレセニリン１阻害を確実にする化合物 | |
| CN108329387B (zh) | 癌症相关的肿瘤特异转录本lin28b-tst及其用途 | |
| JPH07149654A (ja) | アンギオゲニンの抑制剤 | |
| CN111139299A (zh) | Josd2蛋白在制备治疗恶性肿瘤药物中的应用 | |
| CN113398270B (zh) | 一种治疗骨巨细胞瘤的方法 | |
| CN116715761B (zh) | 一种治疗性单克隆抗体及应用 |